Network analysis of osteoporosis provides a global view of associated comorbidities and their temporal relationships

[1]  A. Moltó,et al.  Comorbidity management in spondyloarthritis , 2020, RMD Open.

[2]  J. Callaghan,et al.  The Inaccuracy of ICD-10 Coding in Revision Total Hip Arthroplasty and Its Implication on Revision Data. , 2020, The Journal of arthroplasty.

[3]  V. Moreno,et al.  MorbiNet: multimorbidity networks in adult general population. Analysis of type 2 diabetes mellitus comorbidity , 2020, Scientific Reports.

[4]  S. Chong,et al.  Estimation of Prevalence of Osteoporosis Using OSTA and Its Correlation with Sociodemographic Factors, Disability and Comorbidities , 2019, International journal of environmental research and public health.

[5]  K. Saag,et al.  Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid Arthritis , 2019, Current Rheumatology Reports.

[6]  Arif Khan,et al.  Comorbidity network for chronic disease: A novel approach to understand type 2 diabetes progression , 2018, Int. J. Medical Informatics.

[7]  M. Puth,et al.  Prevalence and comorbidity of osteoporosis– a cross-sectional analysis on 10,660 adults aged 50 years and older in Germany , 2018, BMC Musculoskeletal Disorders.

[8]  Shih-Yi Lin,et al.  Risk of osteoporosis in thyroid cancer patients using levothyroxine: a population-based study , 2018, Current medical research and opinion.

[9]  Fu-Huang Lin,et al.  Increased risk of osteoporosis in patients with primary biliary cirrhosis , 2018, PloS one.

[10]  K. Riklund,et al.  Decrease in bone mineral density during three months after diagnosis of early rheumatoid arthritis measured by digital X-ray radiogrammetry predicts radiographic joint damage after one year , 2017, Arthritis Research & Therapy.

[11]  Jin Hee Kim,et al.  Network analysis of human diseases using Korean nationwide claims data , 2016, J. Biomed. Informatics.

[12]  Ciro Casanova,et al.  COPD comorbidities network , 2015, European Respiratory Journal.

[13]  James F. Wilson,et al.  Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. , 2014, Rheumatology.

[14]  D. Mannino,et al.  Ageing and the epidemiology of multimorbidity , 2014, European Respiratory Journal.

[15]  Naren Ramakrishnan,et al.  Modeling temporal relationships in large scale clinical associations , 2013, J. Am. Medical Informatics Assoc..

[16]  Sang Min Park,et al.  Prevalence, awareness, and treatment of osteoporosis among Korean women: The Fourth Korea National Health and Nutrition Examination Survey. , 2012, Bone.

[17]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[18]  E. Vicari,et al.  L-thyroxin treatment and post-menopausal osteoporosis: relevance of the risk profile present in clinical history. , 2008, Minerva ginecologica.

[19]  M. Gerstein,et al.  Getting connected: analysis and principles of biological networks. , 2007, Genes & development.

[20]  A. Tosteson,et al.  Incidence and Economic Burden of Osteoporosis‐Related Fractures in the United States, 2005–2025 , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  M. Appetecchia.  Effects on Bone Mineral Density by Treatment of Benign Nodular Goiter with Mildly Suppressive Doses of L-Thyroxine in a Cohort Women Study , 2005, Hormone Research in Paediatrics.

[22]  D. Towler,et al.  Osteogenic regulation of vascular calcification: an early perspective. , 2004, American journal of physiology. Endocrinology and metabolism.

[23]  Y. Ben-Shlomo,et al.  A life course approach to chronic disease epidemiology: conceptual models, empirical challenges and interdisciplinary perspectives. , 2002, International journal of epidemiology.

[24]  M. Baldini,et al.  Treatment of benign nodular goitre with mildly suppressive doses of L‐thyroxine: effects on bone mineral density and on nodule size , 2002, Journal of internal medicine.

[25]  P. Geusens,et al.  Differential Expression of Bone Matrix Regulatory Proteins in Human Atherosclerotic Plaques , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[26]  S. Adami,et al.  A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. , 2000, The Journal of rheumatology.

[27]  J. Eisman,et al.  Mortality after all major types of osteoporotic fracture in men and women: an observational study , 1999, The Lancet.

[28]  C. Albanese,et al.  A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre. , 1995, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[29]  E. Barrett-Connor,et al.  Thyroid Hormone Use and Bone Mineral Density in Elderly Women , 1994 .

[30]  E. Barrett-Connor,et al.  Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen. , 1994, JAMA.

[31]  E. Itoi,et al.  Bone mineral density of postmenopausal women with rheumatoid arthritis depends on disease duration regardless of treatment , 2015, Journal of Bone and Mineral Metabolism.

[32]  S. Maggi,et al.  Epidemiologic link between osteoporosis and cardiovascular disease. , 2009, Journal of endocrinological investigation.

[33]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.